BridgeBio Pharma近日披露，其口服药物Infigratinib在为期52周的临床试验中，针对睡眠呼吸暂停和中耳炎两大适应症，呈现出相较于安慰剂更为有利的疗效趋势。这一阶段性成果为该候选药物的后续开发注入了信心，也引发了市场对该公司在呼吸及耳鼻喉领域布局的重新审视。尽管数据尚未达到统计学显著性差异，但所展现出的临床信号仍值得关注。分析人士指出，Infigratinib作为一种成纤维细胞生长因子受体（FGFR）抑制剂，其作用机制或在此类非肿瘤适应症中开辟新的应用路径。公司方面表示，将持续推进相关临床项目，并期待在后续更大规模研究中进一步验证该疗法的有效性与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.